Cancer research at BESSY II: Binding Mechanisms of Therapeutic Substances Deciphered
The study is displayed on the cover of the journal Chemmedchem. © Chemmedchem/VCH Wiley
In tumor cells, the DNA is altered in comparison to normal body cells. How such changes can be prevented or inhibited is an exciting field of research with great relevance for the development of cancer treatments. An interdisciplinary team has now analysed the possible binding mechanisms in certain therapeutic substances from the tetrazole hydrazide group using protein crystallography at BESSY II.
Certain proteins such as human histone demethylases, including the KDM4 protein, play a role in the development of tumour cells. They bind to the DNA and modify it so that the cell can become cancerous. Therapeutic substances that are able to inhibit or even reverse such changes are of particular interest.
Biochemist Prof. Dr. Udo Heinemann from the Max Delbrück Centre in Berlin-Buch is investigating such processes. In cooperation with chemists led by Prof. Dr. Andreas Link from the University of Greifswald and the team led by Dr. Manfred Weiss at the HZB, he has now investigated how and where certain therapeutic substances from the tetrazole hydrazide group dock to these protein molecules and thus inhibit their harmful effect.
KDM4 protein crystals analysed
Link initially produced variations of tetrazole hydrazide substances. For structural analysis, crystals had to be grown from KDM4 proteins - a difficult task that Dr. Piotr Malecki and Manfred Weiss had taken on at the HZB. The KDM4 protein crystals were then soaked in a specific substance before being analyzed with strong X-rays on the MX beamlines of BESSY II. A refined analysis showed not only the three-dimensional architecture of the KDM4 protein, but also exactly where the active substances had docked to the KDM4 molecule.
"This class of substances has not yet been structurally investigated," explains Manfred Weiss. And Udo Heinemann from the MDC explains: "We will now evaluate where there are opportunities to dock even stronger within the 3D structure of the KDM4. Then we might also be able to develop drugs that inhibit the KDM4 even more and thus have the potential to become a therapeutic."
- How carbonates influence CO2-to-fuel conversionResearchers from the Helmholtz Zentrum Berlin (HZB) and the Fritz Haber Institute of the Max Planck Society (FHI) have uncovered how carbonate molecules affect the conversion of CO2 into valuable fuels on gold electrocatalysts. Their findings reveal key molecular mechanisms in CO2 electrocatalysis and hydrogen evolution, pointing to new strategies for improving energy efficiency and reaction selectivity.
- Peat as a sustainable precursor for fuel cell catalyst materialsIron-nitrogen-carbon catalysts have the potential to replace the more expensive platinum catalysts currently used in fuel cells. This is shown by a study conducted by researchers from the Helmholtz-Zentrum Berlin (HZB), Physikalisch-Technische Bundesanstalt (PTB) and universities in Tartu and Tallinn, Estonia. At BESSY II, the team observed the formation of complex microstructures within various samples. They then analysed which structural parameters were particularly important for fostering the preferred electrochemical reactions. The raw material for such catalysts is well decomposed peat.
- Helmholtz Investigator Group on magnonsDr Hebatalla Elnaggar is setting up a new Helmholtz Investigator Group at HZB. At BESSY II, the materials scientist will investigate so-called magnons in magnetic perovskite thin films. The aim is to lay the foundations for future terahertz magnon technology: magnonic devices operating in the terahertz range could process data using a fraction of the energy required by the most advanced semiconductor devices, and at speeds up to a thousand times faster.